Sugi Predict

Sugi Predict / Targets / ERP44

ERP44

Endoplasmic reticulum resident protein 44 · Q9BS26 · ERP44 on Sugi Atlas →

0 patent compounds predicted against ERP44, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ERP44 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes PHASE4UNKNOWN
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women PHASE4COMPLETED
Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy PHASE3COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops PHASE2UNKNOWN
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer PHASE2WITHDRAWN
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection PHASE2COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis PHASE2COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
PBA Use for Treatment of ATF6-/- Patients EARLY_PHASE1SUSPENDED
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism EARLY_PHASE1UNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Tracking Neurodegeneration in Early Wolfram Syndrome nanCOMPLETED
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Fatty Acids Lipidome and Oxidative Stress in Liver Transplantation nanUNKNOWN
Effect of Protein on Endoplasmic Reticulum Stress nanNOT_YET_RECRUITING
sCD163 in ALS Patients nanCOMPLETED
Predicting Pancreatic Necrosis Using mitDNA nanUNKNOWN
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms nanCOMPLETED
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders nanUNKNOWN
Detection of Circulating Biomarkers of Immunogenic Cell Death nanCOMPLETED
Mitoquines in COPD nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ERP44 binder may also engage these)

ProteinNameSimilarity
Q3T0L2 — 1.000 Q3T0L2 →
Q9D1Q6 — 1.000 Q9D1Q6 →
Q8BXZ1 — 0.964 Q8BXZ1 →
Q5R875 — 0.957 Q5R875 →
Q96JJ7 — 0.955 Q96JJ7 →
Q6GQI7 — 0.953 Q6GQI7 →
ENPP2 Autotaxin 0.952 landscape →
Q5M854 — 0.952 Q5M854 →
Q9R1E6 — 0.951 Q9R1E6 →
Q64610 — 0.950 Q64610 →
Q9HCM2 — 0.947 Q9HCM2 →
Q9UM21 — 0.947 Q9UM21 →
Q6NYU2 — 0.946 Q6NYU2 →
CSGALNACT1 Chondroitin sulfate N-acetylgalactosaminyltransferase 1 0.946 landscape →
A1A4K5 — 0.946 A1A4K5 →
Q5XIK2 — 0.946 Q5XIK2 →
Q8R4G0 — 0.945 Q8R4G0 →
Q5E9T6 — 0.945 Q5E9T6 →
Q6AZH6 — 0.944 Q6AZH6 →
Q1EGL1 — 0.944 Q1EGL1 →
Q9Y2I2 — 0.944 Q9Y2I2 →
P46412 — 0.944 P46412 →
B2KI42 — 0.944 B2KI42 →
Q659X0 — 0.944 Q659X0 →
Q8BJQ9 — 0.944 Q8BJQ9 →
Q4R5B4 — 0.944 Q4R5B4 →
Q66PG3 — 0.944 Q66PG3 →
Q4R854 — 0.943 Q4R854 →
Q28BP9 — 0.943 Q28BP9 →
Q6GMK0 — 0.943 Q6GMK0 →